Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 0.41 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.41 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.41 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.41 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.41 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.41 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.41 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126196 | 0.98 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| Iodide SCHEMBL28724212 | 0.96 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL6458019 | 0.92 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL31434318 | 0.90 | DPP4 (0.40) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| Bicarbonate SCHEMBL26607954 | 0.89 | LMNA (0.41) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL14569047 | 0.89 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL16946344 | 0.87 | FAAH (0.42) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL29021832 | 0.87 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL21361147 | 0.87 | DPP4 (0.36) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL13580007 | 0.87 | TSHR (0.35) | GABRA1GABRG2GABRB3GABRB2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223252-A1 | METHOD FOR PRODUCING GLYCOLALDEHYDE DIALKYL ACETAL | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2025-07-10 | — | — | US | claimed |
| CN-120192258-A | Synthesis method of 3-substituted N-aryl pyrrolidine | 兰州大学 | 2025-06-24 | — | — | CN | claimed |
| CN-119462581-A | Preparation method of 3-bromo-7-chlorodibenzo [ b, d ] furan | 中钢天源股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-118666704-A | Synthesis method of formoterol | 山东新时代药业有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118373784-B | One-pot preparation method of 2-aryl benzoxazole and asymmetric sulfoxide | 江苏师范大学 | 2024-09-03 | — | — | CN | claimed |
| CN-118373784-A | One-pot preparation method of 2-aryl benzoxazole and asymmetric sulfoxide | 江苏师范大学 | 2024-07-23 | — | — | CN | claimed |
| CN-118184540-A | Preparation method of 2-fluoro-5-formylbenzonitrile | 福建福瑞明德药业有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117843428-A | endo/exo 3, 4-disubstituted tricyclo [4.2.1.0 2,5 ]Process for preparing non-3, 7-diene compound | 湖南师范大学 | 2024-04-09 | — | — | CN | claimed |
| CN-116903434-A | Copper-catalyzed method for preparing difluoromethyl olefin by hydrodefluorination of trifluoromethyl olefin | 凯美克(上海)医药科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-112920145-B | Method for synthesizing 2, 5-furandicarboxylic acid by visible light catalysis | 新乡学院 | 2023-06-20 | — | — | CN | claimed |
| EP-1836233-A1 | HALOGENATED THIOPHENE MONOMER FOR THE PREPARATION OF REGIOREGULAR POLYTHIOPHENES | Honeywell International Inc. (US) | 2007-09-26 | — | — | EP | claimed |
| EP-1836184-A1 | IMPROVED PROCESS FOR THE KUMADA COUPLING REACTION | Honeywell International Inc. (US) | 2007-09-26 | — | — | EP | claimed |
| US-7262264-B2 | Halogenated thiophene monomer for the preparation of regioregular polythiophenes | HONEYWELL INTERNATIONAL INC. (US) | 2007-08-28 | — | — | US | claimed |
| US-7205414-B2 | Process for the Kumada coupling reaction | HONEYWELL INTERNATIONAL INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2006076150-A1 | IMPROVED PROCESS FOR THE KUMADA COUPLING REACTION | HONEYWELL INTERNATIONAL INC. (US) | 2006-07-20 | — | — | WO | claimed |
| WO-2006076156-A1 | HALOGENATED THIOPHENE MONOMER FOR THE PREPARATION OF REGIOREGULAR POLYTHIOPHENES | HONEYWELL INTERNATIONAL INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-20060155134-A1 | Process for the kumada coupling reaction | HONEYWELL INTERNATIONAL INC. | 2006-07-13 | — | — | US | claimed |
| US-20060155105-A1 | Halogenated thiophene monomer for the preparation of regioregular polythiophenes | HONEYWELL INTERNATIONAL INC. | 2006-07-13 | — | — | US | claimed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155134-A1 | Process for the kumada coupling reaction | KMT5A, KMT5C, KCNT1 | GABRA1 1528/4885GABRG2 1294/4885GABRB3 2763/4885 |
| US-20250223252-A1 | METHOD FOR PRODUCING GLYCOLALDEHYDE DIALKYL ACETAL | ADH1C, ADH1A, ADH5 | GABRA1 3945/4885GABRG2 4096/4885GABRB3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.